NCT07056478View on ClinicalTrials.gov

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions
Sarcopenia in Elderly
Interventions
DRUG

Denosumab (Prolia)

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

DRUG

Zoledronic acide (Aclasta)

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Trial Locations (1)

Unknown

The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
lead

Prince of Wales Hospital, Shatin, Hong Kong

OTHER